Avanos Medical, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 744.60M | 684.10M | 673.30M | 687.80M | 701.20M | 1.9% | |
| Cost of Revenue | (364.70M) | (289.90M) | (293.60M) | (306.50M) | (352.20M) | 14.9% | |
Gross Profit | 379.90M | 394.20M | 379.70M | 381.30M | 349.00M | -8.5% | |
| Operating Expenses | |||||||
| Research & Development | (32.30M) | (30.60M) | (27.20M) | (26.20M) | (23.10M) | -11.8% | |
| Selling, General & Administrative | (260.80M) | (323.10M) | (287.50M) | (315.10M) | (218.30M) | -30.7% | |
| Depreciation & Amortization | (38.30M) | (41.10M) | (43.50M) | (45.50M) | (29.00M) | -36.3% | |
Operating Income (EBIT) | 86.80M | 41.90M | 65.00M | 40.00M | -61.60M | -254.0% | |
| Non-Operating Items | |||||||
| Interest Income | 200.00K | 1.20M | 2.90M | 5.10M | 3.20M | -37.3% | |
| Interest Expense | (3.30M) | (10.00M) | (15.00M) | (12.20M) | (4.00M) | -67.2% | |
| Other Income/Expenses (Net) | -79.50M | -15.20M | -72.90M | -443.30M | -4.60M | -99.0% | |
Income Before Tax | 7.30M | 26.70M | -7.90M | -403.30M | -66.20M | -83.6% | |
| Income Tax Expense | (1.00M) | (5.20M) | (2.00M) | (17.00M) | (1.70M) | -110.0% | |
Net Income | 6.30M | 50.50M | -61.80M | -392.10M | -67.90M | -82.7% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $0 | $1 | $-1 | $-9 | $-1 | -82.9% | |
| Weighted Avg Shares Outstanding | 48.10M | 46.90M | 46.60M | 46.00M | 46.40M | 0.9% | |
| Weighted Avg Shares Outstanding (Diluted) | 48.60M | 47.30M | 46.60M | 46.00M | 46.40M | 0.9% | |
EBITDA | 48.90M | 77.80M | 50.60M | -345.60M | -33.20M | -90.4% |
Explore AVNS
AVNS in the Healthcare
Small Cap